UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000005372
Receipt number R000006372
Scientific Title Study on the effects of supplements containing lutein on spontaneous resolution in eyes with chronic central serous chorioretinopathy
Date of disclosure of the study information 2011/04/16
Last modified on 2015/10/24 20:59:09

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study on the effects of supplements containing lutein on spontaneous resolution in eyes with chronic central serous chorioretinopathy

Acronym

Study on the effects of supplements containing lutein on chronic central serous chorioretinopathy

Scientific Title

Study on the effects of supplements containing lutein on spontaneous resolution in eyes with chronic central serous chorioretinopathy

Scientific Title:Acronym

Study on the effects of supplements containing lutein on chronic central serous chorioretinopathy

Region

Japan


Condition

Condition

chronic central serous chorioretinopathy

Classification by specialty

Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the effects of uptake of supplements containing lutein or placebo on spontaneous resolution in eyes with chronic central serous chorioretinopathy. The impacts of stop-smoking in current smokers will also be evaluated.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

(1) Rate of spontaneous resolution of central serous chorioretinopathy
(2) Changes in macular volume measured by optical coherence tomography

Key secondary outcomes

Best-corrected visual acuity


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

multivitamins, minerals, and luten

Interventions/Control_2

placebo

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

40 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. serous retinal detachment detectable on optical coherence tomography (OCT) with diagnosis of central serous chorioretinopathy (CSC) on the basis of fluorescein angiography
2. chronic CSC with a + any of b, c, d
a. not diagnosed as polypoidal choroidal vasculopathy (PCV) on fluorescein angigraphy
b. visual acuity loss due to persistent serous retinal detachment
c. durations of symptoms over 3 months
d. hyperautofluorescence in the area with serous retinal detachment
3. age over 40 years, obtainable for informed consent
4. Japanese patients
5. patients considered as eligible for study by the investigator

Key exclusion criteria

1. presence of hard exudate or subretinal hemorrhage in or around serous retinal detachment
2. past history of photocoagulation or photodynamic therapy
3. presence of other macular diseases
4. presence of uveitis
5. myopia with -8D or higher
6. past history of vitrectomy
7. hazy media causing difficulties in fundus examinations
8. active exudative age-related macular degeneration in a fellow eye
9. allergic to lutein, anti-oxidants, and minerals
10. daily take of lutein, anti-oxidants, or other supplements
11. pregnant or planned for pregnancy
12. undergone intraocular surgeries within the previous 6 months
13. judged by the investigator to be ineligible for other reasons

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Tsutomu Yasukawa

Organization

Nagoya City University Graduate School of Medical Sciences

Division name

Department of Ophthalmology and Visual Science

Zip code


Address

1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan

TEL

052-853-8251

Email

yasukawa@med.nagoya-cu.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Tsutomu Yasukawa

Organization

Nagoya City University Graduate School of Medical Sciences

Division name

Department of Ophthalmology and Visual Science

Zip code


Address

Kawasumi 1, Mizuho-cho, Mizuho-ku, Nagoya, Aich 467-8601, JAPAN

TEL

052-853-8251

Homepage URL


Email

yasukawa@med.nagoya-cu.ac.jp


Sponsor or person

Institute

Nagoya City University Graduate School of Medical Sciences

Institute

Department

Personal name



Funding Source

Organization

Santen Pharmacuetical Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

大阪大学病院(大阪府)、九州大学病院(福岡県)、駿河台日本大学病院(東京)、名古屋市立大学病院(名古屋)、福島県立医科大学(福島県)
Osaka University Hospital, Osaka; Kyushu University Hospital, Fukuoka; Surugadai Nihon University Hospital, Tokyo; Nagoya City University Hospital, Nagoya; Fukushima Prefectural University, Fukushima


Other administrative information

Date of disclosure of the study information

2011 Year 04 Month 16 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2010 Year 08 Month 27 Day

Date of IRB


Anticipated trial start date

2011 Year 01 Month 01 Day

Last follow-up date

2014 Year 04 Month 30 Day

Date of closure to data entry

2014 Year 05 Month 31 Day

Date trial data considered complete

2014 Year 06 Month 30 Day

Date analysis concluded

2014 Year 09 Month 30 Day


Other

Other related information



Management information

Registered date

2011 Year 04 Month 04 Day

Last modified on

2015 Year 10 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006372


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name